Arrowhead Pharmaceuticals Inc.

33.72-0.7400-2.15%Vol 744.52K1Y Perf -61.85%
Jun 27th, 2022 16:00 DELAYED
BID33.01 ASK34.50
Open34.65 Previous Close34.46
Pre-Market- After-Market33.72
 - -  - -%
Target Price
75.90 
Analyst Rating
Strong Buy 1.22
Potential %
125.09 
Finscreener Ranking
★★★+     51.82
Insiders Trans % 3/6/12 mo.
-/-93/-94 
Value Ranking
★★+     48.55
Insiders Value % 3/6/12 mo.
-/-99/-100 
Growth Ranking
★★★     51.50
Insiders Shares Cnt. % 3/6/12 mo.
-/-99/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
10.76 
Earnings Rating
Sell
Market Cap3.57B 
Earnings Date
4th Aug 2022
Alpha0.06 Standard Deviation0.24
Beta1.41 

Today's Price Range

32.8935.00

52W Range

26.8191.00

5 Year PE Ratio Range

-50.50106.80

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
10.23%
1 Month
-1.40%
3 Months
-24.70%
6 Months
-48.96%
1 Year
-61.85%
3 Years
27.25%
5 Years
1 968.71%
10 Years
801.60%

TickerPriceChg.Chg.%
ARWR33.72-0.7400-2.15
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.00
0.05
0.06
-
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-45.00
-41.30
-120.90
-41.18
RevenueValueIndustryS&P 500US Markets
263.42M
2.49
14.70
61.66
Earnings HistoryEstimateReportedSurprise %
Q02 20220.390.415.13
Q01 2022-0.22-0.60-172.73
Q04 20210.04-0.61-1 625.00
Q03 2021-0.08-0.29-262.50
Q02 2021-0.09-0.26-188.89
Q01 20211.00-0.20-120.00
Q04 20200.34-0.48-241.18
Q03 2020-0.07-0.13-85.71
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.45-9.76Negative
9/2022 QR-0.45-9.76Negative
9/2022 FY-1.037.21Positive
9/2023 FY-1.65-7.14Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.45
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume744.52K
Shares Outstanding105.74K
Shares Float90.56M
Trades Count13.01K
Dollar Volume25.11M
Avg. Volume936.67K
Avg. Weekly Volume1.08M
Avg. Monthly Volume888.61K
Avg. Quarterly Volume840.54K

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock closed at 33.72 per share at the end of the most recent trading day (a -2.15% change compared to the prior day closing price) with a volume of 744.52K shares and market capitalization of 3.57B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Arrowhead Pharmaceuticals Inc. CEO is Christopher Anzalone.

The one-year performance of Arrowhead Pharmaceuticals Inc. stock is -61.85%, while year-to-date (YTD) performance is -49.14%. ARWR stock has a five-year performance of 1968.71%. Its 52-week range is between 26.81 and 91, which gives ARWR stock a 52-week price range ratio of 10.76%

Arrowhead Pharmaceuticals Inc. currently has a PE ratio of -26.70, a price-to-book (PB) ratio of 6.81, a price-to-sale (PS) ratio of 11.69, a price to cashflow ratio of 21.20, a PEG ratio of 2.32, a ROA of -15.77%, a ROC of -23.61% and a ROE of -25.61%. The company’s profit margin is -41.18%, its EBITDA margin is -41.30%, and its revenue ttm is $263.42 Million , which makes it $2.49 revenue per share.

Of the last four earnings reports from Arrowhead Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Arrowhead Pharmaceuticals Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Arrowhead Pharmaceuticals Inc. is Strong Buy (1.22), with a target price of $75.9, which is +125.09% compared to the current price. The earnings rating for Arrowhead Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arrowhead Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arrowhead Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.57, ATR14 : 2.38, CCI20 : 68.71, Chaikin Money Flow : 0.07, MACD : -1.13, Money Flow Index : 65.59, ROC : -1.23, RSI : 53.97, STOCH (14,3) : 85.76, STOCH RSI : 1.00, UO : 61.17, Williams %R : -14.24), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arrowhead Pharmaceuticals Inc. in the last 12-months were: Christopher Anzalone (Sold 0 shares of value $-821 027 ), Christopher Anzalone (Sold 211 388 shares of value $11 873 844 ), Douglas B. Given (Buy at a value of $43 472), Douglas B. Given (Sold 5 000 shares of value $326 200 ), James Hamilton (Sold 25 625 shares of value $1 654 591 ), Kenneth Myszkowski (Sold 40 000 shares of value $2 467 941 ), Marianne De Backer (Sold 4 500 shares of value $291 177 ), Martin Javier San (Sold 19 500 shares of value $1 351 589 ), Mauro Ferrari (Sold 3 400 shares of value $227 188 ), Michael S. Perry (Sold 4 500 shares of value $291 192 ), William D. Waddill (Sold 4 500 shares of value $291 244 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
8 (88.89 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (11.11 %)
1 (11.11 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.22
Strong Buy
1.22
Strong Buy
1.29

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

CEO: Christopher Anzalone

Telephone: +1 626 304-3400

Address: 177 E. Colorado Boulevard, Pasadena 91105, CA, US

Number of employees: 232

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

69%31%

Bearish Bullish

64%36%

News

Stocktwits